Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Release

Printer Friendly Version View printer-friendly version
<< Back
Spring Bank Pharmaceuticals to Present Results from In Vivo Studies of SB 11285, a Novel STING agonist for Immuno-Oncology, at Keystone Symposia

HOPKINTON, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc., (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced two abstracts on SB 11285, its most advanced STING (Stimulator of INterferon Genes) agonist product candidate for the potential treatment of certain cancers, have been accepted for presentation at the 2017 Keystone Symposia: Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology (C7), to be held at the Fairmont Chateau Whistler in Whistler, British Columbia (Canada) on March 19-23, 2017.

Details of Spring Bank’s poster presentations are as follows:

Title: A Novel Class of STING Agonists for Immuno-oncology
Date and Time: Monday March 20, 2017
Poster Number: 1036
Session info: Poster Session 1

Title: Characterization of SB 11285 as a novel STING Agonist for Immuno-oncology
Date and Time: Thursday March 23, 2017
Poster Number:  4074
Session info: Poster Session 4

About Keystone Symposia Conference Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology (C7)
The fields of cancer immunology and immunotherapy continue to make great strides in providing both a comprehensive understanding of the basic mechanisms underlying tumor-immune system interactions and applying this knowledge to the development of effective immune-based cancer therapies. This Keystone Symposia meeting is organized to highlight recent insights into the complex roles of immune components and pathways in controlling or alternatively promoting cancer and to showcase recent uses of cancer vaccines, checkpoint blocking strategies, adoptive cell therapies and cellular engineering approaches, either as mono- or combinatorial therapies, that have resulted in durable, effective and safe therapeutic responses to an increasing number of cancer patients. Part of the meeting will also focus on new, developing technologies that are likely to expand our capacity to monitor the effects of cancer immunotherapy with a precision, refinement and at a level that has not been possible in the past.

About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus (HBV). SB 9200 has been designed to selectively activate within infected cells the cellular proteins, retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2), which have been implicated in the body’s immune response to viral infections. Spring Bank believes that SB 9200 may play an important role in antiviral therapy by modulating the body’s immune response through its mechanisms of action to fight viral infections such as HBV. The company is also conducting preclinical studies on its most advanced STING agonist candidate, SB 11285. For more information, please visit www.springbankpharm.com.

Contact:
Jonathan Freve
Chief Financial Officer
Spring Bank Pharmaceuticals
(508) 473-5993
jfreve@springbankpharm.com

Primary Logo

Spring Bank Pharmaceuticals Inc.